Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 26, 2025 07:00 ET | Source: Tango Therapeutics Sub, Inc

Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is...
November 12, 2025 07:00 ET | Source: Tango Therapeutics Sub, Inc

Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

BOSTON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled...
November 04, 2025 09:00 ET | Source: Tango Therapeutics Sub, Inc

Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

– Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months– – Combination studies with RAS(ON) inhibitors ongoing, data...
October 29, 2025 07:00 ET | Source: Tango Therapeutics Sub, Inc

Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before...
October 23, 2025 07:20 ET | Source: Tango Therapeutics Sub, Inc

Tango Therapeutics Announces $225 Million Financing

BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...
October 23, 2025 07:00 ET | Source: Tango Therapeutics Sub, Inc

Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

– 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% – – Combination studies with RAS(ON) inhibitors ongoing, data...
October 06, 2025 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025

BOSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision...
August 26, 2025 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled...
August 05, 2025 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

– First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors – – First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant...
July 22, 2025 07:00 ET | Source: Tango Therapeutics, Inc.

Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report second quarter 2025 financial results on August 5, 2025, before the open of the...